Study Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)BIOLOGICAL
D0: 0.1×106/Kg ～ 2.0×106/Kg; Cells will be infused intravenously.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital Zhejiang University School of Medicine | Hangzhou | Zhejiang | China |